ScandiBio Therapeutics

info@scandibio.com
  • About Us
    • Our Science
    • The Team
  • Clinical Studies
    • Phase I/II: SERINE
    • Phase I: METABOLIC COFACTORS
    • Phase II: NAFLD
    • Phase II: AD/PD
    • Phase II: COVID-19
  • Publications
  • News
  • Contact

Gina Kennedy

ScandiBio Therapeutics   →  Company   →  Gina Kennedy
14
Feb
Date February 14, 2018

Gina Kennedy

Long established fact that a reader will be distracted by the readable content of a page when looking at it’s layout. The point of using Lorem Ipsum

Author SCANDIBIO

Categories

  • News 10

Recent Posts

  • Metabolic Cofactor Supplementation Reduces Recovery Time in COVID-19 Patients by Nearly 30%October 6, 2020
  • A review article has been published discussing the current status of COVID-19 therapiesJuly 24, 2020
  • A review article has been published regarding the host-microbiome interactions in neurodegenerative diseasesJuly 8, 2020
  • ScandiBio Therapeutics has completed a directed share issue amounting to 5 million SEKJune 1, 2020
  • A review article has been published about the use of AI-based systems biology for drug development to treat neurodegenerative diseasesMay 19, 2020

Archives

  • October 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
Copyright © 2020 ScandiBio Therapeutics. All rights reserved.